Keyphrases
Breast Cancer
44%
Neoadjuvant Chemotherapy
36%
Overall Survival
34%
Polymorphism
34%
Breast Cancer Patients
30%
Metastatic Colorectal Cancer (mCRC)
29%
Tumor
29%
Human Epidermal Growth Factor Receptor 2 (HER2)
25%
Cisplatin
24%
Disease-free Survival
24%
Metastatic Breast Cancer
24%
Genotype
23%
Confidence Interval
21%
Pharmacogenetics
21%
Pathological Complete Response
20%
Cyclophosphamide
19%
Clinical Outcomes
19%
Multivariate Analysis
19%
Anti-EGFR
19%
Non-small Cell Lung Cancer (NSCLC)
19%
Epidermal Growth Factor Receptor
18%
Non-small Cell Lung Cancer Patients
17%
Early Breast Cancer
17%
Colorectal Cancer
17%
Ki-67
15%
Triple-negative Breast Carcinoma
15%
Breast Carcinoma
15%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
15%
Thymidylate Synthase
14%
5-fluorouracil (5-FU)
14%
Progression-free Survival
14%
DNA Repair Genes
14%
Hazard Ratio
14%
SNP
14%
Docetaxel
13%
Prognostic Factors
13%
Genetic Variants
12%
Odds Ratio
12%
Cancer Drugs
12%
Circulating Tumor Cells
12%
Ifosfamide
12%
Irinotecan
12%
Vascular Endothelial Growth Factor
12%
Gene Variants
12%
Receptor-based
12%
Capecitabine
12%
Advanced Colorectal Cancer
12%
Quantitative PCR
12%
Overexpression
12%
Peripheral Blood
12%
Medicine and Dentistry
Breast Cancer
100%
Neoplasm
68%
Neoadjuvant Chemotherapy
32%
Malignant Neoplasm
31%
Breast Carcinoma
30%
Chemotherapy
26%
Overall Survival
25%
Triple Negative Breast Cancer
24%
Non Small Cell Lung Cancer
21%
Metastatic Carcinoma
20%
Odds Ratio
18%
Biological Marker
17%
Messenger RNA
16%
Systemic Therapy
15%
Metastatic Breast Cancer
13%
Circulating Tumor Cell
12%
Pharmacogenetics
12%
Trastuzumab
12%
Estrogen Receptor
12%
Disease Free Survival
12%
Diseases
12%
Epidermal Growth Factor Receptor 2
11%
Gamma Urogastrone
11%
Multivariate Analysis
11%
Cyclophosphamide
11%
Upregulation
10%
Cancer Specific Survival
10%
Ductal Carcinoma
10%
Carcinoma
9%
Epidermal Growth Factor Receptor
9%
BRCA1
8%
Docetaxel
8%
Genetic Variability
7%
Carboplatin
7%
Cisplatin
7%
Quantitative Reverse Transcription Polymerase Chain Reaction
7%
down Regulation
7%
Fluorouracil
7%
DNA Repair
7%
Anthracycline
7%
Gene Expression
7%
Oncology
7%
Anticarcinogen
7%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
7%
Neoadjuvant Therapy
7%
Prognostic Factor
7%
Lung Cancer
7%
Sentinel Lymph Node
7%
Uvomorulin
6%
Proportional Hazards Model
6%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
62%
Chemotherapy
45%
Neoplasm
40%
Malignant Neoplasm
39%
Overall Survival
36%
Epidermal Growth Factor Receptor
31%
Metastatic Colorectal Cancer
28%
Cisplatin
24%
Non Small Cell Lung Cancer
21%
Biological Marker
20%
Cyclophosphamide
19%
Progression Free Survival
18%
Disease Free Survival
18%
Recurrent Disease
16%
Adverse Event
16%
Breast Carcinoma
15%
Vasculotropin
15%
Docetaxel
14%
Disease
14%
Pharmacogenetics
14%
Colorectal Carcinoma
13%
Trastuzumab
12%
Lung Cancer
12%
Oxaliplatin
12%
Irinotecan
12%
Ifosfamide
12%
Metastatic Breast Cancer
9%
Messenger RNA
9%
Fluorouracil
9%
Epirubicin
9%
Endocrine Therapy
8%
Paget Nipple Disease
8%
Phase II Trials
8%
Epidermal Growth Factor Receptor 2
8%
Gamma Urogastrone
8%
Doxorubicin
8%
Metastasis
8%
Paclitaxel
7%
Receptor
7%
Nanoparticle
7%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
7%
Neutropenia
6%
Lapatinib
6%
Vindesine
6%
Capecitabine
6%
Amphiregulin
6%
Alkaline Phosphatase
6%
Acute Toxicity
6%
Somatomedin C Receptor
6%
First-Line Chemotherapy
6%